Repligen
RGEN
Repligen (RGEN) Fails to deliver data
Key failure to deliver metrics for Repligen :
- Last SEC data release: 2024-04-30
- Last 15 days FTD volume: $5.29 M
- Last 3 months FTD volume: $11.94 M
- Last year FTD volume: $0.10 B
Failures to deliver for Repligen (RGEN) - 3 months history
Number of shares, 3 months chartBiweekly Failures to deliver volume for Repligen (RGEN) - since 2013
Volume in USD (price x number of shares), data since 2013Repligen (RGEN) Failure to deliver volume, Year over Year
| Year | Volume (Price x Shares) | Change |
|---|---|---|
| 2024 | $13.89 M | -87.13% |
| 2023 | $0.10 B | 60.05% |
| 2022 | $67.43 M | 90.89% |
| 2021 | $35.32 M | -76.42% |
| 2020 | $0.14 B | 197.63% |
| 2019 | $50.34 M | -29.09% |
| 2018 | $70.99 M | 835.37% |
| 2017 | $7.59 M | 22.08% |
| 2016 | $6.21 M | -19.68% |
| 2015 | $7.74 M | -7.23% |
| 2014 | $8.34 M | 721.71% |
| 2013 | $1.01 M |
FTD volume in the last 3 months for similar companies or competitors
| Company | FTD volume (3months) | FTD volume (1 year) | Country |
|---|---|---|---|
 Pfizer PFE | $10.32 M | $0.31 B | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | $0.10 B | $0.34 B | 🇺🇸 USA |
 General Electric GE | $0.66 B | $0.88 B | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $0.23 B | $0.32 B | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $0.19 M | $1.68 M | 🇺🇸 USA |
 Novavax NVAX | $36.99 M | $0.31 B | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $15.31 M | $34.27 M | 🇺🇸 USA |
 Bio-Techne TECH | $8.16 M | $29.32 M | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.77 M | $7.27 M | 🇺🇸 USA |
 Charles River Laboratories
CRL | $7.8 M | $21.21 M | 🇺🇸 USA |